Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: Long-term follow-up results

European Journal of Haematology

Volumn 81, Issue 3, 2008, Pages 165-169

  Medeot, Marta ^a   Zaja, Francesco ^a   Vianelli, Nicola ^b   Battista, Marta ^a   Baccarani, Michele ^b   Patriarca, Francesca ^a   Soldano, Franca ^a   Isola, Miriam ^a   De Luca, Stefano ^a   Fanin, Renato ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b Istituto di Ematologia Ed Oncologia Medica L e A Seragnoli   (Italy)

Author keywords

Immune thrombocytopenic purpura; Long term activity; Rituximab

Indexed keywords

AZATHIOPRINE; CHLORPHENIRAMINE; CYCLOSPORIN A; DANAZOL; DAPSONE; ELTROMBOPAG; IMMUNOGLOBULIN; PARACETAMOL; PREDNISONE; RITUXIMAB; STEROID; VALACICLOVIR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL INDICATOR; CLINICAL OBSERVATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LOW DRUG DOSE; MALE; OPPORTUNISTIC INFECTION; PREMEDICATION; PRIORITY JOURNAL; RELAPSE; SERUM SICKNESS; SPLENECTOMY; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; TIME; TREATMENT OUTCOME;

EID: 49349113937     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01100.x     Document Type: Article

References (13)

1. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiophatic thrombocytopenic purpura. Ann Int Med 2007 146: 25 44.
2. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year [abstract]. Blood 2006 108: 479.
3. Zaja F, Vianelli N, Sperotto A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003 88: 538 46.
4. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 88: 3 40.
5. National Cancer Institute. Common Toxicity Criteria Version 3.0 (CTC), 2003 (http://ctep.cancer.gov/reporting/CTC-3.html).
6. Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005 90: 72 7.
7. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008 371: 395 403.
8. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 357: 2237 47.
9. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004 125: 232 9.
10. Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 2007 14: 642 6.
11. Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V, Filì C, Tani M, Baccarani M, Fanin R. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006 34: 571 2.
12. Godeau B, Fain O, Porcher R, et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase 2 study [abstract]. Blood 2006 108: 478.
13. Zaja F, Mazza P, Vianelli N, et al. A prospective randomized study of rituximab and dexamethasone vs dexamethasone alone in ITP [abstract]. Blood 2007 110: 567.